Efficacy and Safety of TCA vs. ECA for the Treatment of AIN in HIV-positive Patients (TECAIN)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02615860 |
|
Recruitment Status :
Completed
First Posted : November 26, 2015
Last Update Posted : November 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anal Intraepithelial Neoplasia (AIN) in HIV-infected Patients | Other: Topical 85% trichloroacetic acid (TCA) Procedure: Surgical electrocautery (ECA) | Not Applicable |
Anal human papillomavirus (HPV)-infection and HPV-induced AIN, an anal cancer precursor, are very frequent in HIV-positive patients (HIV+), especially in men who have sex with men (MSM), but also in women. Consequently, HIV+ have a strongly increased risk for anal cancer. Screening for and treatment of AIN are recommended in HIV+, although only two RCT on AIN treatment have been published. We plan a multicenter, unblinded, non-inferiority RCT that evaluates the efficacy and safety of 2 high-resolution anoscopy (HRA)-guided treatment options for AIN: topical application of trichloroacetic acid (TCA) and surgical treatment with electrocautery (ECA).
ECA was the best option for intra-anal AIN in a recent randomized controlled trial (RCT). TCA, an inexpensive and established therapy for genital warts, has been evaluated for AIN only in a retrospective pilot study that showed clearance rates comparable to those found for ECA, with possibly less adverse events (AE). Our primary hypothesis is that cost-saving and simple TCA is non-inferior to ECA. 2800 HIV+ will be screened by HRA in 9 proctological centers and 560 HIV+ with histologically confirmed intra-anal AIN will be randomized (1:1) to receive up to 4 treatments with TCA or ECA within 12 weeks. The primary efficacy endpoint is clinical (HRA) and histological resolution of AIN 4 weeks after the last treatment. Secondary endpoints comprise recurrence of AIN 24 weeks after end of therapy, the number of interventions, AE, and the influence of HPV parameters such as anal HPV-types, viral load and HPV-oncogene-mRNA.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 560 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy and Safety of Topical Trichloroacetic Acid vs. Electrocautery for the Treatment of Anal Intraepithelial Neoplasia in HIV-positive Patients (TECAIN) - a Randomized Controlled Trial |
| Actual Study Start Date : | November 2015 |
| Actual Primary Completion Date : | March 31, 2020 |
| Actual Study Completion Date : | December 31, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Topical 85% trichloroacetic acid (TCA)
AIN lesions are treated with trichloric acid
|
Other: Topical 85% trichloroacetic acid (TCA)
In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
Other Name: Topical treatment with trichloroacetic acid (TCA) |
|
Active Comparator: Surgical electrocautery (ECA)
AIN lesions are treated with electrocautery
|
Procedure: Surgical electrocautery (ECA)
In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
Other Name: Device: Electrocauter |
- Therapeutic success (success rate) defined as clinically (HRA) and histologically confirmed resolution (normal histology) or regression (from AIN2/3 to AIN1) of AIN [ Time Frame: Four weeks after the last treatment within TECAIN ]The primary endpoint is therapeutic success (success rate) defined as clinically (HRA) and histologically confirmed resolution (normal histology) or regression (from AIN 2/3 to AIN1) of AIN four weeks after the last treatment within TECAIN. Patients not showing up at this mandatory follow-up appointment will be counted as treatment failure. Histologically confirmed resolution/regression 4 (to 8) weeks after therapy has been the primary endpoint in the two published RCTs and in several pilot studies. Clearance of AIN after treatment is the most relevant endpoint for patients, since AIN can rapidly progress to AC in HIV+ patients.
- Recurrence of AIN at the previously treated sites [ Time Frame: 24 weeks after the end of TECAIN treatment ]
- Number of interventions needed during the 12 weeks TECAIN treatment period. [ Time Frame: 4 weeks after the end of TECAIN treatment ]Additional treatments are possible after baseline, but they are not mandatory, if the lesions are cleared. So 4 weeks after each treatment the investigator checks, if the lesions are cleared and decides if he does another treatment or if the patient can progress to the follow up
- Pain of the proctologic AIN treatments [ Time Frame: Up to 16 weeks after study start ]Additional treatments are possible after baseline, but they are not mandatory, if the lesions are cleared. So 4 weeks after each treatment the investigator checks, if the lesions are cleared and decides if he does another treatment or if the patient can progress to the follow up
- Anal HPV types, HPV multiplicity, HPV DNA load and HPV oncogene mRNA [ Time Frame: Baseline, 4 and 24 weeks after the end of TECAIN treatment ]
- Recurrence of AIN or new lesions [ Time Frame: 6 months after completion of TECAIN treatment in previously treated areas ]
- Duration of treatment phase [ Time Frame: 24 weeks after the end of TECAIN treatment ]
- Adverse events [ Time Frame: During the whole study up to 36 weeks ]
- Treatment costs [ Time Frame: 24 weeks after the end of TECAIN treatment ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV positive patients
- Legally eligible patients and age ≥ 18 years
- Sufficient knowledge of the German language, spoken and written
- Patient is willing and able to appear regularly to the treatment- and follow-up appointments
- Clinically visible AIN-lesion, which was confirmed by histopathology (findings not older than 2 weeks after the date of collection and removal date no longer than 16 weeks prior to baseline)
- Written informed consent
Exclusion Criteria:
- Currently diagnosed anal cancer or anal cancer in anamnesis (within the last 5 years)
- Acute life-threatening disease
- Participation in a proctologic study within the last 30 days
- Participation in this study at an earlier date
- Simultaneous participation in another clinical trial, which excludes the participation in this study
- Simultaneous topical and systemic treatments wtih medications that affect the study outcome, such as immunomodulatory substances: Interferone, imiquimod or systemic glucocorticosteroids
- lactation
- Pregnancy: In patients of childbearing age, a pregnancy has to be ruled out by pregnancy test or other suitable methods.
- Women of childbearing potential without adequate contraceptive protection.
- Contraindication for using trichloroacetic acid or electrocautery
- Patients in whom general anesthesia in the treatment of AIN is necessary already at study start
- Other serious intra-anal and proctologic disorders, which make additional proctologic or systemic treatments necessary, which influence the study result, such as an active Crohn's disease, which must be treated locally and systemically with immunosuppressives or an active proctitis.
- Patients who have been vaccinated before baseline against HPV
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02615860
| Germany | |
| Universitätsklinikum Essen, Klinik für Dermatologie | |
| Essen, Nordrheinwestfalen, Germany, 45147 | |
Publications:
| Responsible Party: | Stefan Esser M.D., Dr. med., University Hospital, Essen |
| ClinicalTrials.gov Identifier: | NCT02615860 |
| Other Study ID Numbers: |
01KG1425 |
| First Posted: | November 26, 2015 Key Record Dates |
| Last Update Posted: | November 8, 2022 |
| Last Verified: | November 2022 |
|
HIV-infection anal cancer (AC) anal cancer prevention anal dysplasia anal intraepithelial neoplasia (AIN) |
human papillomavirus (HPV) HPV-induced anal cancer precursor lesions electrocautery (ECA) topical trichloroacetic acid (TCA) treatment. |
|
Neoplasms Carcinoma in Situ Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |